[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370164-105":59,"doc-detail-370164-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dynamics-of-vegf-a-angiopoietin-2-and-hif-1-levels-in-patients-with-brain-metastases-treated-with-cyberknife-radiosurgery","Dynamics of VEGF-A, Angiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery","","The study evaluates how neoangiogenesis and hypoxia biomarkers change in patients with brain metastases (BM) undergoing robotic stereotactic radiosurgery with the CyberKnife system. It prospectively follows 66 patients with oligometastatic disease from lung cancer and other primary tumors, measuring serum Angiopoietin-2, HIF-1α, and VEGF-A. Post-treatment analyses show statistically significant decreases from baseline to 6 months in both groups, though levels remain higher than healthy controls. Results support integrating molecular markers for improved clinical decision-making and risk assessment.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dynamics-of-vegf-a-angiopoietin-2-and-hif-1-levels-in-patients-with-brain-metastases-treated-with-cyberknife-radiosurgery/370164/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dynamics-of-vegf-a-angiopoietin-2-and-hif-1-levels-in-patients-with-brain-metastases-treated-with-cyberknife-radiosurgery/370164.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What biomarkers are measured in the study?","Question",{"text":113,"@type":114},"The study measures serum Angiopoietin-2, HIF-1α, and VEGF-A in patients with brain metastases.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are patients treated in this research?",{"text":118,"@type":114},"Patients with oligometastatic brain metastases (up to 4 metastases) are treated with CyberKnife robotic stereotactic radiosurgery.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the key finding about biomarker levels after treatment?",{"text":122,"@type":114},"Across both patient groups, Angiopoietin-2, HIF-1α, and VEGF-A show statistically significant decreases from baseline to 6 months, while remaining higher than healthy controls.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370164,1790276175,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Dynamics of VEGF-А , А ngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery  \nVeselin Popov, MD, PhD, MHM 1,2 , Gabriela Raycheva, MD, PhD 1,2, and Zhanet Grudeva-Popova, MD, PhD, MH 1,2  \nTechnology in Cancer Research & Treatment  \nVolume 24: 1-7  \n© The Author(s) 2025  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338251313945](DOI: 10.1177/15330338251313945)[ ](DOI: 10.1177/15330338251313945)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nAbstract  \nThe contemporary concept of carcinogenesis summarizes the role of hypoxia, neoangiogenesis, and hemostasis, including in the stage of progression and metastasis of the tumor process. Metastatic disease is a serious therapeutic challenge for any oncological condition. The purpose of this study was to evaluate the dynamics of speciﬁc indicators of neoangiogenesis and hypoxia as potential biomarkers for therapeutic efﬁcacy or risk of disease progression in patients with brain metastases (BM) undergoing robotic stereotactic radiosurgery. Two groups of patients (lung cancer and other types of cancers) with oligometastatic disease and brain metastases were included. The patients (n = 66) were treated CyberKnife system. Human Angiopoietin-2, Hypoxia inducible factor 1 α (HIF-1 α) and human Vascular Endothelial Growth Factor-А (VEGF-А) were measured in this prospective longitudinal study. Analysis of human Angiopoietin-2, HIF-1 α, human VEGF-A in the post-treatment period showed a statistically signiﬁcant decrease between the baseline and the 6 months post-treatment time point in both patient groups. The baseline value of serum VEGF-А in the group with lung cancer decreased by 40%, Аngiopoietin-2-by 48%, HIF-1 α –by 43%. In the group with other types of cancers, VEGF-А decreased by 54.75%, Аngiopoietin-2–by 52%, HIF-1 α –by 39.5%. Despite the signiﬁcant reduction, the levels remained signiﬁcantly higher in both groups than in healthy controls. This study underscores the potential of integrating molecular markers like VEGF-A, Angiopoietin-2, and HIF-1 α into clinical decision-making to enhance outcomes for patients with brain metastases undergoing RSRS.  \nKeywords  \nsolid tumors, human Angiopoietin-2, Hypoxia inducible factor 1 (HIF-1 α), human VEGF-A, brain metastases, robotic stereotactic radiosurgery, CyberKnife  \nReceived: September 21, 2024; Revised: November 27, 2024; Accepted: December 20, 2024.  \nIntroduction  \nMetastatic disease presents a serious clinical and therapeutic challenge for any oncological condition. Brain metastases (BM) are detected in about 10% of patients at the time of diagnosis.1 The true incidence of BM, which develops in approximately one-third of patients with carcinoma, is not well known. Lung carcinoma (over 40%), breast carcinoma (about 20%), and melanoma (20%) are the most common primary sites for the development of BM.2 The appearance of BM in any oncological localization limits systemic drug therapy due to the pharmacokinetic speciﬁcity of medications and the bloodbrain barrier. The median survival for untreated patients with BM is about 1–2 months, a period that may increase after the application of local ablative methods such as radiosurgery.  \nIn contrast to the widespread use of molecular-genetic markers in medical oncology, their use for predictive/prognostic purposes in radiotherapy (RT) remains extremely limited. Given the current capabilities of personalized medicine, thereis growing interest in combining it with local ablative methods in patients with oligometastatic disease, including  \n1 Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, Bulgaria  \n2 UMHAT “Sv. Georgi”- Plovdiv, Bulgaria  \nCorresponding Author:  \nV. Popov, Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, Bulgaria; UMHAT “Sv. Georgi”- Plovdiv, Bulgaria.  \nEmail:","cbCaioZoKq6xWrFV","https://ap.wps.com/l/cbCaioZoKq6xWrFV","pdf",1153852,"English","# Abstract\n# Introduction\n# Material and Methods","[{\"question\":\"What biomarkers are measured in the study?\",\"answer\":\"The study measures serum Angiopoietin-2, HIF-1α, and VEGF-A in patients with brain metastases.\"},{\"question\":\"How are patients treated in this research?\",\"answer\":\"Patients with oligometastatic brain metastases (up to 4 metastases) are treated with CyberKnife robotic stereotactic radiosurgery.\"},{\"question\":\"What is the key finding about biomarker levels after treatment?\",\"answer\":\"Across both patient groups, Angiopoietin-2, HIF-1α, and VEGF-A show statistically significant decreases from baseline to 6 months, while remaining higher than healthy controls.\"}]","Dynamics of VEGF-A, Angiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery | PDF",1790187125,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f27d4bf6aee79906c4d107a190a17189.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11b313ae13e9b6933f8e52f9649eb456.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/321824b593c09dfa7fb7101ae62be6e1.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69f61c495536ba252ae90f88876c89b5.webp",980,1272]